Eris Lifesciences Limited (BOM:540596)

Market Cap	221.54B
Revenue (ttm)	28.79B
Net Income (ttm)	3.52B
Shares Out	n/a
EPS (ttm)	25.81
PE Ratio	62.97
Forward PE	40.65
Dividend	14.70 (0.91%)
Ex-Dividend Date	Feb 13, 2025

Volume	9,586
Average Volume	16,540
Open	1,701.10
Previous Close	1,735.25
Day's Range	1,575.10 - 1,758.40
52-Week Range	988.95 - 1,909.55
Beta	n/a
RSI	48.26
Earnings Date	Aug 4, 2025

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measureme...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 3,620
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540596

Financial Performance

In 2024, Eris Lifesciences's revenue was 28.79 billion, an increase of 44.59% compared to the previous year's 19.91 billion. Earnings were 3.52 billion, a decrease of -10.24%.